Patents by Inventor Friedrich Scheiflinger

Friedrich Scheiflinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI MIF ANTIBODIES
    Publication number: 20150023978
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Application
    Filed: January 17, 2014
    Publication date: January 22, 2015
    Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SA
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20140335071
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: April 7, 2014
    Publication date: November 13, 2014
    Applicant: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • CHARACTERIZATION OF CHO-MIF GENE AND PROTEIN, AND USE THEREOF
    Publication number: 20140287443
    Abstract: The present invention is concerned with the specific and highly sensitive detection of specific CHO-MIF (macrophage migration inhibitory factor from Chinese Ovarian Hamster cell line) complexes in the production of anti-MIF antibodies. The present invention is further concerned with the provision of specific antibodies which can be used for a CHO-MIF detection method. The present invention is also concerned with a CHO MIF knockout cell line and use thereof. The present invention also provides preparations obtained from recombinant production in CHO cell lines which are essentially free of CHO-MIF.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 25, 2014
    Inventors: Randolf J. Kerschbaumer, Dirk Voelkel, Gerhard Antoine, Friedrich Scheiflinger, Geert C. Mudde
  • Polymer von Willebrand factor-conjugates
    Patent number: 8835388
    Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 16, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Peter Turecek, Jueren Siekmann
  • OXMIF AS A DIAGNOSTIC MARKER
    Publication number: 20140248638
    Abstract: The present invention pertains to the recognition that a specific oxMIF form of MIF is useful as a diagnostic marker in (MIF-related) diseases, in particular for example monitoring of disease progression. The present invention also pertains to the respective use of a diagnostic kit and a respective diagnostic assay and pertains to advantageous respective antibodies.
    Type: Application
    Filed: October 4, 2012
    Publication date: September 4, 2014
    Inventors: Michael Thiele, Randolf J. Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger
  • Procoagulant peptides
    Patent number: 8822638
    Abstract: A peptide or peptide derivative comprising: (i)?WDLYFEIVW; (SEQ?ID?NO:?1) or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: September 2, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • Immunoadsorption of anti-von Willebrand factor cleaving protease antibodies
    Patent number: 8795999
    Abstract: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: August 5, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Barbara Plaimauer, Gerhard Antoine
  • FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
    Publication number: 20140186323
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
    Patent number: 8703429
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxler Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Composition exhibiting a von Willebrand Factor (vWF) protease activity with the amino acid sequence AAGGILHLELLV
    Patent number: 8703426
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: April 22, 2014
    Assignee: Baxter Innovations GmbH
    Inventors: Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Anti MIF antibodies
    Patent number: 8668909
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: March 11, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • METHODS AND SYSTEMS FOR SCREENING COMPOSITIONS COMPRISING NON-ANTICOAGULANT SULFATED POLYSACCHARIDES
    Publication number: 20140051657
    Abstract: Aspects of the invention include methods for identifying one or more NASP (non-anticoagulant sulfated polysaccharide) compositions that are suitable for treating a subject having a blood coagulation disorder. In practicing methods according to certain embodiments, NASP compositions are evaluated by determining the coagulation activity and chemical makeup of the NASP composition and the molecular structure of the NASP. Systems for practicing methods of the invention as well as compositions suitable for treating a subject having a blood coagulation disorder are also described.
    Type: Application
    Filed: August 12, 2013
    Publication date: February 20, 2014
    Inventors: Michael Dockal, Friedrich Scheiflinger, Zhenqing Zhang, Susanne Till, Sabine Knappe, Christina Szabo
  • Methods for Treating Bleeding Disorders
    Publication number: 20140050717
    Abstract: A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor X1; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor X1-dependent manner.
    Type: Application
    Filed: August 29, 2013
    Publication date: February 20, 2014
    Inventors: Michael Dockal, Friedrich Scheiflinger, Peter Turecek
  • Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
    Patent number: 8637007
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Marie-Christine Canavaggio
  • Methods and compositions for treating bleeding disorders
    Patent number: 8632991
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: January 21, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
  • Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
    Patent number: 8586538
    Abstract: The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: November 19, 2013
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Koenraad Mertens, Arend N. Bovenschen, Jan Voorberg, Manfred Rieger, Friedrich Scheiflinger
  • Procoagulant peptides
    Patent number: 8563688
    Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: October 22, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Friedrich Scheiflinger, Michael Dockal
  • APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS
    Publication number: 20130267584
    Abstract: The present invention provides compositions and methods for modulating TFPI protein plasma concentration and TFPI protein function. Such modulation can be used to treat blood disorders such as bleeding disorders and clotting disorders.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 10, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Michael Dockal, Friedrich Scheiflinger
  • TFPI INHIBITORS AND METHODS OF USE
    Publication number: 20130259863
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 3, 2013
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Factor VIII polypeptide having factor VIII:C activity
    Patent number: 8546332
    Abstract: Factor VIII polypeptides having FVIII:C activity that contain modifications in the A3 and/or C1 and/or C2 domains of the sequence of the light chain of Factor VIII, characterized by the binding affinity to low density lipoprotein receptor protein, and methods for producing the same.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: October 1, 2013
    Assignee: Stichting Sanquin Bloedvoorziening
    Inventors: Petrus Johannes Lenting, Jan Aart Van Mourik, Koenraad Mertens, Hans Pannekoek, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger